217 related articles for article (PubMed ID: 35476316)
1. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
[TBL] [Abstract][Full Text] [Related]
4. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
[TBL] [Abstract][Full Text] [Related]
5. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
6. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA
Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512
[TBL] [Abstract][Full Text] [Related]
7. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
9. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
10. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Saha C; Harrison C
Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis.
Tremblay D; Cavalli L; Sy O; Rose S; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e463-e466. PubMed ID: 35120852
[No Abstract] [Full Text] [Related]
12. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
[TBL] [Abstract][Full Text] [Related]
13. Fedratinib in myelofibrosis.
Mullally A; Hood J; Harrison C; Mesa R
Blood Adv; 2020 Apr; 4(8):1792-1800. PubMed ID: 32343799
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Verstovsek S; Mesa R; Talpaz M; Kiladjian JJ; Harrison CN; Oh ST; Vannucchi AM; Rampal R; Scott BL; Buckley SA; Craig AR; Roman-Torres K; Mascarenhas JO
Haematologica; 2022 Jul; 107(7):1599-1607. PubMed ID: 34551507
[TBL] [Abstract][Full Text] [Related]
15. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
Schiffer M; Kowalski A; Zhao J; Bewersdorf JP; Lewis RS; Zeidan AM
Drugs Today (Barc); 2020 Dec; 56(12):755-768. PubMed ID: 33332482
[TBL] [Abstract][Full Text] [Related]
16. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
17. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
18. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Mesa RA; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Abraham P; Lord-Bessen J; Tang D; Guo S; Ye X; Harrison CN
Hemasphere; 2021 May; 5(5):e553. PubMed ID: 33969273
[TBL] [Abstract][Full Text] [Related]
20. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
